What type of study is this?

December 8, 2025BloodOpen Access

Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows belumosudil improves outcomes in pediatric graft-versus-host disease, suggesting early treatment timing benefits.

Belumosudil achieved a 77% overall response rate at 12 weeks in pediatric patients with graft-versus-host disease, indicating its effectiveness.
Key predictors include early intervention within three months, which resulted in a 92% response rate compared to 50% for delayed treatment.
The analysis of 34 pediatric patients with steroid-refractory graft-versus-host disease highlights the importance of treatment timing on outcomes.
With high response rates in skin and pulmonary organs, belumosudil's favorable safety profile supports its inclusion in pediatric therapy protocols.

Chunfu Li (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows belumosudil improves outcomes in pediatric graft-versus-host disease, suggesting early treatment timing benefits.

Belumosudil achieved a 77% overall response rate at 12 weeks in pediatric patients with graft-versus-host disease, indicating its effectiveness.
Key predictors include early intervention within three months, which resulted in a 92% response rate compared to 50% for delayed treatment.
The analysis of 34 pediatric patients with steroid-refractory graft-versus-host disease highlights the importance of treatment timing on outcomes.
With high response rates in skin and pulmonary organs, belumosudil's favorable safety profile supports its inclusion in pediatric therapy protocols.

Chunfu Li (2025) studied this question.

View Full Paper

Ask AI

Bookmark